Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
NCT06483139
Acute Kidney Injury, Blood Protein Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT Number: NCT01209169
The purpose of this study is to collect blood and urine samples that may help identify and validate biomarkers for the early detection and risk assessment of acute kidney injury (AKI).
Looking for future studies?
Notify Me21 year and older
All sexes
Observational
University Clinic for Internal Medicine, Innsbruck, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Males and females 21 years of age or older;
Subjects enrolled (first sample collection) from ED or Floor admitted to the ICU within 24 hours of enrollment; Subjects enrolled from ICU admitted to the ICU within the 24 hours prior to enrollment; Expected to remain in the ICU for at least 48 hours after enrollment; Use of indwelling urinary catheter as standard care expected for at least 48 hours after enrollment; At least one of the following acute conditions within 24 hours prior to enrollment:
(Respiratory SOFA score of ≥ 2 (PaO2/FiO2 <300)and/or Cardiovascular SOFA score of ≥ 1 (MAP < 70 mm Hg and/or any vasopressor required).
Patient (or authorized representative) able and willing to provide written informed consent for study participation.
Exclusion criteria
Special populations including women with known pregnancy, prisoners or institutionalized individuals;Previous renal transplantation;Known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria. Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment; Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic);Patient meets any of the following:Active bleeding with an anticipated need for > 4 units PRBC;Hemoglobin < 7 g/dL;Any other condition that in the physician's opinion would contraindicate drawing serial blood samples for clinical study purposes.
Time frame: 10/2010 to 2/2013
Primary outcome measure: Identification and Validation of Biomarkers from Acutely ill patients at risk for AKI. (N=744) Secondary outcomes including follow-up (N=890).
Astute Medical, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06483139
Acute Kidney Injury, Blood Protein Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT07688733
Acute Kidney Injury, Blood Protein Disorders
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT07654010
Acute Kidney Injury, Female Urogenital Diseases
Malatya, Osmaniye, Turkey (Türkiye)
View Trial DetailsNCT05033652
Acute Kidney Injury, Chronic Disease
Alès, France
View Trial Details